VRTX
Price:
$468
Market Cap:
$120.79B
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clin...[Read more]
Industry
Biotechnology
IPO Date
1991-07-24
Stock Exchange
NASDAQ
Ticker
VRTX
According to Vertex Pharmaceuticals Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -237.56. This represents a change of -1563.16% compared to the average of 16.24 of the last 4 quarters.
The mean historical PE Ratio of Vertex Pharmaceuticals Incorporated over the last ten years is 5.52. The current -237.56 PE Ratio has changed -430423.80% with respect to the historical average. Over the past ten years (40 quarters), VRTX's PE Ratio was at its highest in in the June 2017 quarter at 443.13. The PE Ratio was at its lowest in in the September 2016 quarter at -126.50.
Average
5.52
Median
22.45
Minimum
-160.15
Maximum
141.54
Discovering the peaks and valleys of Vertex Pharmaceuticals Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 194.95%
Maximum Annual PE Ratio = 141.54
Minimum Annual Increase = -188.38%
Minimum Annual PE Ratio = -160.15
Year | PE Ratio | Change |
---|---|---|
2023 | 28.97 | 30.12% |
2022 | 22.26 | -7.86% |
2021 | 24.16 | 6.69% |
2020 | 22.65 | -52.59% |
2019 | 47.77 | 137.69% |
2018 | 20.10 | -85.80% |
2017 | 141.54 | -188.38% |
2016 | -160.15 | 194.95% |
2015 | -54.30 | 43.69% |
2014 | -37.79 | 0.67% |
The current PE Ratio of Vertex Pharmaceuticals Incorporated (VRTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
25.13
5-year avg
29.16
10-year avg
5.52
Vertex Pharmaceuticals Incorporated’s PE Ratio is less than BioMarin Pharmaceutical Inc. (62.30), less than Sarepta Therapeutics, Inc. (257.91), less than Seagen Inc. (-57.36), greater than Alnylam Pharmaceuticals, Inc. (-428.77), less than Intellia Therapeutics, Inc. (-3.76), less than Editas Medicine, Inc. (-1.53), less than Beam Therapeutics Inc. (-13.42), less than Ginkgo Bioworks Holdings, Inc. (-0.32), less than BioNTech SE (-37.92), less than Moderna, Inc. (-4.77), less than Regeneron Pharmaceuticals, Inc. (28.30), less than Viking Therapeutics, Inc. (-61.76), less than PTC Therapeutics, Inc. (-5.05), less than Reata Pharmaceuticals, Inc. (-89.36), less than Intercept Pharmaceuticals, Inc. (-13.55), less than Krystal Biotech, Inc. (49.72), less than Madrigal Pharmaceuticals, Inc. (-10.23), less than CRISPR Therapeutics AG (-14.26), less than Caribou Biosciences, Inc. (-1.26), less than Verve Therapeutics, Inc. (-2.45),
Company | PE Ratio | Market cap |
---|---|---|
62.30 | $16.01B | |
257.91 | $12.29B | |
-57.36 | $43.15B | |
-428.77 | $31.68B | |
-3.76 | $2.00B | |
-1.53 | $296.09M | |
-13.42 | $1.92B | |
-0.32 | $975.05M | |
-37.92 | $21.38B | |
-4.77 | $28.02B | |
28.30 | $122.67B | |
-61.76 | $6.00B | |
-5.05 | $2.43B | |
-89.36 | $6.57B | |
-13.55 | $794.69M | |
49.72 | $5.29B | |
-10.23 | $5.30B | |
-14.26 | $3.80B | |
-1.26 | $155.42M | |
-2.45 | $473.47M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vertex Pharmaceuticals Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vertex Pharmaceuticals Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Vertex Pharmaceuticals Incorporated's PE Ratio?
How is the PE Ratio calculated for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the highest PE Ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the 3-year average PE Ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the 5-year average PE Ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
How does the current PE Ratio for Vertex Pharmaceuticals Incorporated (VRTX) compare to its historical average?